EMEA-001050-PIP01-10-M05
Key facts
Invented name |
Taltz
|
Active substance |
ixekizumab
|
Therapeutic area |
Dermatology
|
Decision number |
P/0087/2020
|
PIP number |
EMEA-001050-PIP01-10-M05
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of psoriasis
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Eli Lilly Nederland B.V.
E-mail: EU_paediatric@lilly.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|